GlassScriptPhysician profile
Antony A Farias
NPI 1891022141
$8,400.26
in general payments reported to CMS, 2019-2025
26 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,554 · 2020: $1,800 · 2021: $657 · 2022: $318 · 2023: $792 · 2024: $1,152 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,026 · Education: $44.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,025.71 |
| Education | $44.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $3,427.59 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $960.79 | 2021-2025 | Farxiga |
| Novo Nordisk As | $624.87 | 2019 | |
| Aurinia Pharma U.S., INC. | $581.11 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $379.74 | 2021-2025 | Velphoro, Velphoro |
| Ardelyx, INC. | $269.25 | 2023-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $268.41 | 2023-2025 | Tarpeyo |
| Novo Nordisk INC | $267.55 | 2022-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $257.99 | 2021-2025 | |
| Nxstage Medical, INC. | $240.19 | 2023 | Nxstage System One, Nxstage Cartridge Express |
| Otsuka America Pharmaceutical, INC. | $208.23 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $144.23 | 2021-2023 | Jesduvroq |
| Amgen INC. | $127.70 | 2024-2025 | Repatha, Krystexxa |
| Metuchen Pharmaceuticals | $118.72 | 2019 | |
| Mallinckrodt Hospital Products INC. | $89.95 | 2023-2024 | Acthar, Terlivaz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.57 | 2023-2024 | Jardiance |
| Medtronic, INC. | $59.15 | 2023 | Ellipsys Vascular Access System |
| Akebia Therapeutics INC | $50.17 | 2024 | Vafseo, Auryxia |
| Cycle Pharmaceuticals INC | $50.00 | 2024-2025 | Tiopronin, Venxxiva |
| Novartis Pharmaceuticals Corporation | $45.59 | 2024-2025 | |
| Travere Therapeutics, INC. | $42.16 | 2023-2025 | |
| Scpharmaceuticals INC. | $35.26 | 2025 | |
| Horizon Therapeutics Plc | $26.27 | 2022 | |
| Surmodics, INC. | $25.26 | 2024 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy, Sublime Microcatheter, 018, 200cm, Straight |
| Kyowa Kirin, INC. | $20.66 | 2025 | |
| Cormedix INC. | $17.85 | 2025 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antony Farias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.